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The heat shock response in neurons and astroglia and its role in
neurodegenerative diseases
Abstract
Protein inclusions are a predominant molecular pathology found in numerous neurodegenerative
diseases, including amyotrophic lateral sclerosis and Huntington's disease. Protein inclusions form in
discrete areas of the brain characteristic to the type of neurodegenerative disease, and coincide with the
death of neurons in that region (e.g. spinal cord motor neurons in amyotrophic lateral sclerosis). This
suggests that the process of protein misfolding leading to inclusion formation is neurotoxic, and that cellautonomous and non-cell autonomous mechanisms that maintain protein homeostasis (proteostasis)
can, at times, be insufficient to prevent protein inclusion formation in the central nervous system. The
heat shock response is a pro-survival pathway induced under conditions of cellular stress that acts to
maintain proteostasis through the up-regulation of heat shock proteins, a superfamily of molecular
chaperones, other co-chaperones and mitotic regulators. The kinetics and magnitude of the heat shock
response varies in a stress- and cell-type dependent manner. It remains to be determined if and/or how
the heat shock response is activated in the different cell-types that comprise the central nervous system
(e.g. neurons and astroglia) in response to protein misfolding events that precede cellular dysfunctions in
neurodegenerative diseases. This is particularly relevant considering emerging evidence demonstrating
the non-cell autonomous nature of amyotrophic lateral sclerosis and Huntington's disease (and other
neurodegenerative diseases) and the destructive role of astroglia in disease progression. This review
highlights the complexity of heat shock response activation and addresses whether neurons and glia
sense and respond to protein misfolding and aggregation associated with neurodegenerative diseases, in
particular Huntington's disease and amyotrophic lateral sclerosis, by inducing a pro-survival heat shock
response.
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Abstract
Protein inclusions are a predominant molecular pathology found in numerous neurodegenerative diseases,
including amyotrophic lateral sclerosis and Huntington’s disease. Protein inclusions form in discrete areas of the
brain characteristic to the type of neurodegenerative disease, and coincide with the death of neurons in that
region (e.g. spinal cord motor neurons in amyotrophic lateral sclerosis). This suggests that the process of protein
misfolding leading to inclusion formation is neurotoxic, and that cell-autonomous and non-cell autonomous
mechanisms that maintain protein homeostasis (proteostasis) can, at times, be insufficient to prevent protein
inclusion formation in the central nervous system. The heat shock response is a pro-survival pathway induced
under conditions of cellular stress that acts to maintain proteostasis through the up-regulation of heat shock
proteins, a superfamily of molecular chaperones, other co-chaperones and mitotic regulators. The kinetics and
magnitude of the heat shock response varies in a stress- and cell-type dependent manner. It remains to be
determined if and/or how the heat shock response is activated in the different cell-types that comprise the
central nervous system (e.g. neurons and astroglia) in response to protein misfolding events that precede cellular
dysfunctions in neurodegenerative diseases. This is particularly relevant considering emerging evidence demonstrating
the non-cell autonomous nature of amyotrophic lateral sclerosis and Huntington’s disease (and other neurodegenerative
diseases) and the destructive role of astroglia in disease progression. This review highlights the complexity of heat shock
response activation and addresses whether neurons and glia sense and respond to protein misfolding and aggregation
associated with neurodegenerative diseases, in particular Huntington’s disease and amyotrophic lateral sclerosis, by
inducing a pro-survival heat shock response.
Keywords: Neurodegeneration, Amyotrophic lateral sclerosis, Huntington’s disease, Proteostasis, Heat shock response,
Heat shock factor 1, Motor neurons, Striatal neurons, Astroglia

Background
Neurodegenerative diseases (NDs), such as amyotrophic
lateral sclerosis (ALS) and Huntington’s disease (HD), are
thought to manifest through either a loss of function of the
wild-type (WT) protein or toxic gain-of-function as a result
of its oligomerization and aggregation [1]. The neuronspecific degeneration observed in discrete regions of the
brain in NDs suggests that specific neuronal sub-types are
particularly vulnerable to protein misfolding and aggregation. This may be the result of: (i) a post-mitotic inability to
* Correspondence: heathe@uow.edu.au
Illawarra Health and Medical Research Institute and School of Biological
Sciences, University of Wollongong, Northfields Ave, Wollongong 2522,
Australia

dilute toxic protein species through cell-division; (ii) an
age-related decline in the systems that maintain protein
homeostasis (proteostasis); (iii) a failure of the proteostasis
network to detect pathogenic protein aggregates; or (iv) a
combination of these factors [2–4].
Molecular chaperones are a central component of the
proteostasis network as they act to facilitate the correct
folding of nascent polypeptides, maintain partially-folded
protein intermediates in folding-competent states and
re-fold damaged proteins [5–8]. A recent comprehensive
analysis of the human “chaperome” identified 332
chaperone genes, 142 of which correspond to the heat
shock protein subfamilies (Hsp90, Hsp70, Hsp60, Hsp40
and sHsps) [4]. The Hsps are a family of evolutionarily
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conserved chaperones with diverse functions in proteostasis. In addition to their well characterized molecular
chaperone functions, Hsps also stabilize the cytoskeleton, regulate stress responses, mitigate apoptotic signalling and shuttle damaged proteins for degradation by the
ubiquitin proteasome system or by autophagy [9, 10].
There is a dramatic up-regulation of Hsp expression in
cells upon induction of the heat shock response (HSR).
The activation of this pathway is a primary defense
mechanism that protects cells from stress conditions
that promote protein misfolding, aggregation and cell
death. It has previously been shown that components of
the HSR may be neuroprotective due to their ability to
interact with the earliest misfolded proteins that trigger
pathogenic aggregation. Indeed, numerous studies have
shown that Hsps can prevent the aggregation of various
disease-associated proteins in vitro, for example, mutant
superoxide dismutase 1 (SOD1) in ALS [11–15]. Heat
shock proteins can also interact with pathogenic proteins in vivo and have been found co-localized with plaques and inclusions in transgenic mouse models of NDs
and patient post-mortem tissues [16–19]. For example,
Hsc70 was co-localized with inclusion bodies in spinal
cord sections of SOD1G93A , SOD1G85R , and SOD1G37R
transgenic mice, and human sporadic ALS cases [17].
The co-localization of Hsps with inclusions suggests that
Hsps are diverted into inclusions and therefore unavailable to perform normal “housekeeping” functions.
Little is known about how and/or if the HSR is induced
in neuronal and glial cells by pathogenic protein aggregation. Elucidating whether the HSR is triggered by protein
aggregation and, if so, the mechanism(s) by which this occurs, is important for future work aimed at developing
proteostasis-modulating therapeutics to ameliorate ND
pathologies. The objectives of this review are to summarize
what is currently known about the activation of the HSR in
different tissues and cell-types during cellular stress, and
explore evidence regarding the involvement of the HSR in
rescuing neurons and astroglia from pathological stress associated with NDs. Due to the diversity in how different
NDs manifest in the CNS (i.e. dysfunction of different neuronal and non-neuronal cell types across different brain regions), this review seeks to provide a comprehensive
summary of the literature surrounding the HSR in cells associated with HD and ALS. We conclude by drawing correlations between our core findings in the HD and ALS
literature with NDs in general. In doing so, progress in this
field of research is evaluated, gaps in our knowledge are
highlighted and possible solutions are discussed.

The HSR
Proteotoxic cellular insults have a common effect of
damaging proteins and inducing the accumulation of
partially-folded protein intermediates. This in turn can
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activate transcription factors and induce the HSR. The
human genome encodes four heat shock transcription
factors (HSF), HSF1 – HSF4, which have unique and
overlapping functions [20]. Heat shock transcription factor 1 is the prime integrator of transcriptional responses
during stress and is responsible for the induction of the
HSR. The role of HSF1 in the activation and attenuation
of the HSR in cells under conditions of cellular stress is
discussed briefly below.
Heat shock transcription factor 1

Heat shock transcription factor 1 is constitutively expressed
in most tissues and cell types and, apart from its role in the
HSR, is involved in a wide range of processes including organismal development, insulin signaling and cancer metastasis (for recent comprehensive reviews see [21, 22]). Posttranslational modifications are critical in modulating the activity of HSF1 [23]: it can be acetylated [24, 25], SUMOylated [26] and extensively phosphorylated [27] (Fig. 1). The
type and site of each post-translational modification have
been predominantly identified by proteomic mass spectrometry and site-directed mutagenesis experiments [22,
23, 28]. Whilst the activation of HSF1 is complex and only
partially understood, previous studies highlight the importance post-translational modifications play in stabilising, activating and inhibiting the transcriptional activity of HSF1
[28]. For example, conversion of HSF1 into a transcriptionally active trimer occurs concurrently with extensive posttranslational modifications including stress-inducible hyperphosphorylation of S230, S326 and T142 [29–31], such that
hyperphosphorylated HSF1 is used as a marker of HSF1 activation [32–35]. Aside from (extensive) phosphorylation,
acetylation and SUMOylation of HSF1 also play important
roles in regulating the strength and duration of the HSR
(for comprehensive reviews see [21, 36]).
HSR activation and attenuation

Under conditions of cellular stress, HSF1 monomers
form activated homo-trimers and translocate into the
nucleus. Trimerization is mediated through the formation of leucine zippers on adjacent HSF1 oligomerization
domains (Fig. 2) [37, 38]. Activated HSF1 trimers bind
to cis-regulatory elements on DNA composed of nGAAn
pentamers (where n is any base), collectively called heat
shock elements [39–42]. The extent and duration of
HSF1-mediated transcription is influenced by the number of heat shock elements, the exact sequence of
nGAAn pentamers in the promoter regions of HSF1 target genes, and post-translational modifications on HSF1
itself [21]. In addition to the rapid up-regulation of Hsp
expression in response to cellular stress, HSF1 also coordinates the expression of many transcriptional and
translational regulators, co-chaperones, ubiquitin, signaling molecules and mitotic regulators [21, 43, 44].

San Gil et al. Molecular Neurodegeneration (2017) 12:65

Page 3 of 20

Fig. 1 Post-translational modifications of HSF1 in relation to the functional domains in the protein. The HSF1 protein consists of a DNA-binding
domain (DBD), four leucine zipper domains (LZD), a regulatory domain (RD) and a transactivating domain (TAD). The proposed sites of serine/
threonine phosphorylation (P), lysine acetylation (A) and phosphorylation-dependent lysine SUMOylation (S) are marked on the HSF1 amino acid
chain. These post-translational modifications are mediated by numerous kinases, acetylases and SUMOylases and act to modulate the stabilization
and activity of HSF1 and thus the strength and duration of the HSR

Heat shock factor 1-mediated transcription is attenuated
by an auto-regulatory mechanism, whereby HSF1-induced
Hsps competitively inhibit HSF1 trimer activity [22, 28].
This negative feedback loop provides an important mechanism by which cells can regulate the activation and attenuation of an HSR via the presence and concentration
of Hsps in the cell. The trimerisation of HSF1 is suppressed by interaction of the monomer with a multichaperone complex composed of Hsp90, co-chaperone
p23 and immunophilin FK506-binding protein 5 [45, 46].
In addition, the chaperonin TRiC/CCT can also interact
with HSF1 to inhibit its activation [47]. Active HSF1 trimers in the nucleus can be inhibited by the binding of
Hsp70 and its co-chaperone Hsp40, possibly through recruitment of the Hsp70-interacting transcriptional corepressor, CoREST [48, 49]. Further characterization of
the mechanisms that modulate HSF1 activity (and therefore, the HSR) may help elucidate additional targets for
therapies that could be used to boost the HSR in the context of disease such as NDs.

The HSR in the mammalian CNS
In mammals, the HSR varies both in terms of kinetics
(i.e. how fast stress-induced transcripts are generated)

and magnitude (i.e. the fold increase in Hsp levels) between tissues and even between cells in the same tissue
[50–52]. Analysis of the human “chaperome” shows that
the constitutive expression of housekeeping chaperones
and co-chaperones varies between tissues [52]. For example, sHsps are overrepresented in skeletal and cardiac
muscle compared to the brain [52]. With regard to inducing the HSR, whole organism hyperthermia results in
an HSR that varies substantially across tissues types [50].
For example, in heat-stressed rats, the kinetics of the response and magnitude of induction where found to vary
between the brain, liver and skin when assessed over
time by northern blot of Hsp70 and Hsp27 stressinduced mRNA [50]. Moreover, cells in the same tissue
can display different capacities to induce the HSR. For
example, cultured astrocytes elicit faster and higher
levels of Hsp70 expression after heat shock (45 °C for
30 min) compared to cultured cortical neurons [51].
These studies strongly suggest that the capacity of a cell
to sense stress and elicit an HSR differs in a cell-type
dependent manner.
An attenuated HSR may be an intrinsic characteristic
of neurons [35, 53–55]. Indeed, this hypothesis is supported by several animal studies that have challenged
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Fig. 2 The activation of HSF1 and its binding to DNA is regulated by a multi-step pathway that involves nuclear accumulation, intramolecular and
intermolecular protein interactions, and post-translational modifications. (1) In the absence of stress, HSF1 is maintained in a monomeric state through
the regulatory actions of several post-translational modifications, intramolecular contacts, and interactions with Hsps in inhibitory complexes. Cellular
stress results in the accumulation of misfolded and damaged proteins, which compete with HSF1 for binding to Hsps. (2) HSF1 monomers are released
and undergo a conformational change conducive to trimerization. (3) Concurrent nuclear accumulation, HSE-binding and hyperphosphorylation of
trimeric HSF1 occur. (4) This process releases RNA PolII from a paused to an active state to initiate the transcription of stress-induced genes. (5)
SUMOylation at K298 and binding of Hsp40/Hsp70 represses the transcriptional activity of HSF1 trimers. (6) Acetylation at K80 disrupts HSF1 binding to
DNA and HSF1 trimers dissociate and re-join the monomeric pool in the cytosol. Stress-inducible Hsps participate in a negative-feedback loop to
inhibit further HSF1 activation

rodents with hyperthermia or ischemic injury and shown
that neurons do not induce Hsp70 expression after exposure to these stressors, whereas surrounding astroglial
cells do [35, 51, 54–59]. These seminal studies show that
under conditions of acute cellular stress, neurons are inherently poor activators of the HSR, whereas astroglia
readily activate the HSR. This prompts the question of
whether neuronal and astroglial cells respond to chronic
ND-relevant stressors (such as protein aggregation) and,
if so, whether there is a difference in the response of
neuronal and astroglial cells to this stress. In an attempt
to address these questions, the remainder of this review
deals with what is known about HSR activation in the
context of two NDs, HD and ALS.
Huntington’s Disease

Huntington’s disease is characterized by the formation of
intracellular inclusions composed primarily of the ubiquitous protein huntingtin (Htt) and by the subsequent death

of striatal medium spiny neurons and cortical pyramidal
neurons [60, 61]. The genetic basis for the pathogenesis of
HD is a CAG codon repeat expansion in the Huntingtin
(HTT) gene, which leads to a mutant protein that contains
an expanded poly-glutamine (polyQ) sequence [62]. Expansions of the polyQ tract beyond 36 glutamines result
in an aggregation-prone Htt protein; the length of the
polyQ-expansion correlates with the age of disease onset
and severity (i.e. the longer the polyQ tract, the earlier the
onset of disease and the more rapid the disease progression) [63]. Well-characterized cell and transgenic mouse
models of HD have been used in investigations into the
impact of the HSR on the pathogenicity of polyQexpansions.
PolyQ-expanded Htt may interact differently with the
proteostasis network compared to other diseaseassociated proteins. Evidence for this comes from studies that have shown that polyQ-expanded Htt103Q (i.e.
Htt with a polyQ stretch of 103 glutamines) partitions
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exclusively into perivacuolar inclusion bodies (IPODs:
Insoluble PrOtein Deposits) that store terminally aggregated proteins [64]. Fluorescence recovery after photobleaching experiments showed that Htt103Q proteins
sequestered into IPODs are immobile [65] indicating
that sequestration into IPODs prevents possible interactions of the aggregated protein with components of
the proteostasis network, exacerbating the formation of
inclusions in cells [64, 66]. Recent evidence also suggests that Htt inclusion body formation deactivates
apoptosis and results in slow necrotic cell death [67]. This
contrasts with quality control partitioning of other
aggregation-prone disease-associated proteins, such as
SOD1, which accumulate in juxtanuclear compartments
(JUNQ: JUxtaNuclear Quality control) for presentation to
molecular chaperones for re-folding and/or the ubiquitin
proteasome system for degradation [64, 66, 68, 69]. Therefore, findings pertaining to the HSR in the context of HD
may uniquely apply to this ND due to the propensity of
polyQ-expanded Htt to misfold directly into terminal aggregates and become stored in IPODs (as opposed to the
JUNQ).
The HSR in striatal neurons

The expression and cellular accumulation of pathogenic
polyQ-expanded Htt is not sufficient to induce an HSR
in cell and animal models of HD. The expression of
Htt91Q does not induce an HSR (as assessed by an
Hsp70 promoter driven EGFP expression construct)
[70]. Notably, the expression of Htt111Q in striatal cells
was not sufficient to up-regulate Hsp expression nor activate HSF1 [32]. Likewise, primary cultures of rat cortical and striatal neurons expressing Htt111Q showed low

levels of Hsp70 mRNA transcripts and protein compared
to cerebellar granule cells, which have high levels of
Hsp70 and are resistant to degeneration [71]. Studies
using transgenic mouse models of HD have demonstrated that there is a reduction in Hsp70 (and other
molecular chaperones) in the brain as the disease progresses (Table 1) [72]. Taken together, these results show
that cells expressing polyQ-expanded Htt do not sense
or respond to this aggregation-prone protein by inducing an HSR.
The expression of polyQ-expanded Htt sensitizes
neurons to heat stress [32, 73]. Heat shock (42 °C for
6 h) of primary murine striatal neurons expressing
pathogenic Htt111Q resulted in a 6-fold increase in caspase activity compared to heat shocked cells expressing
non-pathogenic Htt7Q [32]. Furthermore, cells expressing Htt111Q had a reduced capacity to express Hsp70,
Hsp25 (the mouse orthologue of Hsp27) and Hsp90
after heat shock compared to those expressing Htt7Q
[32]. These findings suggest that expression of polyQexpanded Htt attenuates the capacity of striatal neurons
to up-regulate the expression of Hsps after heat shock,
which is normally a very strong activator of the HSR.
Based on these findings, it is pertinent to question
whether the observed inability of striatal neurons to induce an HSR in the context of HD is the result of insufficient levels of HSF1, a failure to activate HSF1, a lack
of HSF1 binding to DNA, or a combination of these deficiencies (Fig. 3). Quantification of total HSF1 protein
by immunoblot demonstrated that primary striatal neurons expressing Htt111Q, and the striata and cerebella of
HD mouse models, have lower total HSF1 levels compared to controls [32]. New evidence implicates CK2α’

Table 1 List of Hsps and whether their expression is up-regulated (↑), down-regulated (↓), or not changed (No Δ) across rodent
models of HD compared to transgenic WT or non-transgenic mouse controls
Hsps

Transgenic disease models

Tissue or cell type

Reference

HSF1

STHdh(Q111) knock-in mice

IB: 80% ↓striatal and cerebellar tissue homogenates

[32, 74]

αB-c (HSPB5)

R6/2

IB: No Δ whole brain homogenates

[72]

Htt-N171-82Q

IB: No Δ spinal cord homogenates

[79]

R6/2

IB: No Δ whole brain homogenates

[72]

Htt-N171-82Q

IB: No Δ spinal cord homogenates

[79]

Hsp40

R6/2

IB: 60% ↓Hdj1 whole brain homogenates
IB: 25% ↓Hdj2 whole brain homogenates

[72]

Hsp60

R6/2

LC-MS: 4-fold ↓ in protein abundance in the cortex
LC-MS: 4-fold ↑ in protein abundance in the striatum

[80]

Hsp70

STHdh(Q111) knock-in mice

IB: 80% ↓striatal and cerebellar tissue homogenates

[32]

R6/2

IB: ↓ whole brain homogenates
IB: No Δ Hsc70 whole brain homogenates

[72]

Hsp90

R6/2

IB: No Δ Hsp90 whole brain homogenates
IB: No Δ Hsp84 whole brain homogenates

[72]

Hsp105

–

–

–

Hsp25 (HSPB1)

These results are from immunoblot (IB), or liquid chromatography coupled with quantitative mass spectrometry (LC-MS) of affected CNS regions
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Fig. 3 Proposed summary of changes in the HSR and its components in polyQ-expanded Htt over-expression models of HD. Huntington’s disease
onset and progression into late stage is dependent on the molecular pathologies developed in striatal neurons (e.g. formation of polyQexpanded Htt aggregates or IPODs) and astroglia (e.g. decline in GLAST/GLT-1 expression and the secretion of unidentified toxic “factors”). The
susceptibility of striatal neurons to degeneration from HD-associated stresses could be the result of a polyQ-expanded Htt-mediated attenuation
of the HSR. Over-expression of polyQ-expanded Htt in CNS tissues results in a (1) reduction in HSF1 levels. (2) Histone H4 acetylation has been
shown to be a strong promoter of HSF1 binding to DNA of target genes. However, hypoacetylation of histone H4 at HSF1 targets (e.g. Hspa1b,
Hspb1, and Dnajb1) with disease progression can explain (3) the decrease in HSF1 binding to DNA observed in polyQ-expanded Htt expressing
striatal neurons. (4) HD disease progression is also associated with a decline in Hsp70 and Hsp40 family members and (5) a striatal-specific
increase in Hsp60. (6) There have been few investigations regarding HSF1 activation and DNA-binding in astroglia. Therefore, the capacity of
polyQ-expanded Htt over-expressing astroglia to activate HSF1 and induce an HSR is currently unknown

kinase and Fbxw7 Fbox protein (an E3 ubiquitin ligase)
in the enhanced degradation of HSF1 in cells expressing
polyQ-expanded Htt [74]. The proposed model suggests
that polyQ-expanded Htt up-regulates CK2α’ kinase expression and increases the phosphorylation of HSF1 at
S303 and S307. This in turn recruits Fbxw7, which ubiquitinylates phospho-HSF1 targeting it for degradation
by the ubiquitin proteasome system [74]. Enhanced degradation of HSF1 by the proteasome has also been implicated in a mouse model and human post-mortem tissues
of α-synucleinopathies, whereby elevated levels of the
ubiquitin ligase, NEDD4, ubiquitinates HSF1 for degradation [25]. Whilst expression of Htt111Q is not sufficient
to induce HSF1 activation in cerebellar granule cells,
heat shock does result in activated (hyperphosphorylated) HSF1 trimers accumulating in the cell nucleus
[32, 71]. Similarly, HSF1 dissociation from Hsp90, hyperphosphorylation, and nuclear translocation are not impaired in HD mice upon treatment with the Hsp90

inhibitor NVP-HSP990, which is able to penetrate into
the brain [71]. Therefore, there is a reduction in total
HSF1 levels in the striatum; however, HSF1 can become
hyperphosphorylated and translocate into the nucleus in
HD models.
With regard to the DNA binding capacity of HSF1 in
HD models, evidence suggests that the expression of
polyQ-expanded Htt attenuates HSF1 binding to DNA
in striatal cells [73]. Genome-wide chromatin immunoprecipitation (ChIP) experiments demonstrated that in
primary striatal neurons expressing Htt111Q, HSF1 is
only capable of binding 39% of its target genes after heat
shock (1159 bound genes) compared to cells expressing
Htt7Q (2943 bound genes) [73]. Microarray data show
that the reduced HSF1 binding to DNA in heat shocked
cells expressing Htt111Q corresponds with a decline in the
transcription of several Hsps (Dndjb5, Dnajb12 and
Hspb6). Furthermore, mRNA levels of Hsp70, Hsp40 and
Hsp25 were reduced in the cerebral cortices of HD mouse
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models compared to controls following treatment with
NVP-HSP990 [75]. Therefore, since HSF1 activation appears to be unimpaired, low levels of HSF1 and its compromised ability to bind DNA could account for the
observed inability of cells expressing polyQ-expanded Htt
to elicit an HSR. This dysregulation of chaperone gene
expression likely plays a key role in the pathology of HD.
Altered chromatin architecture in HD may explain the
reduced capacity of HSF1 to bind to target genes in
striatal neurons under stress [75–78]. Quantitative PCR
coupled with ChIP analysis after NVP-HSP990 (Hsp90
inhibitor) treatment demonstrated significant hypoacetylation of histone H4 at Hspa1b, Hspb1, Dnajb1 genes in
Htt111Q expressing primary striatal neurons compared to
Htt7Q [75]. Hypoacetylation of these Hsp genes may
change the chromatin landscape sufficiently to interfere
with HSF1 binding to DNA (Fig. 3). Stress-inducible
binding of HSF1 to DNA is associated with histone
acetylation, H3K4 trimethylation, RNA polymerase II
and other co-activators [77]. Furthermore, tetra-acetyl
histone H4 has previously been suggested to be a strong
modulator of HSF1 binding to DNA [77]. Therefore, it
follows that histone H4 hypoacetylation in HD models
may reduce chromatin accessibility of HSF1 at heat
shock genes, consequently impairing the HSR.
At the tissue level, there are several studies that have
investigated Hsp expression, and therefore HSR activation,
in affected and non-affected tissues in mouse models of
HD (Table 1). Immunoblot analysis of whole brain or
spinal cord homogenates from HD mice have shown that
overall there is no change in the total protein levels of the
sHsps Hsp25 or αB-crystallin (αB-c, HSPB5) or Hsp90
family members compared to mice expressing nonpathogenic Htt [72, 79]. Whole tissue homogenates from
HD mice showed a reduction in HSF1, Hsp70, and two
Hsp40 family members (Hdj1 and Hdj2; Fig. 3) [32, 72].
Conversely, striatal homogenates from HD mice were
found to have a 4-fold increase in Hsp60 levels compared
to control mice [80]. A lack of immunohistochemistry in
these studies makes it impossible to determine (i) where
changes occur at the cellular level and (ii), whether small
cell populations or specific cell-types induce an HSR,
which is undetectable in bulk cell analyses. Employing immunohistochemistry in parallel to this work, or more
powerful omics-based single-cell analyses, such as the
proteomics approach undertaken by Sharma et al. [81],
has the potential to resolve cell-type and brain-region
specific differences in the presence or absence of disease.
In this way, cell-type specific differences in the ability to
induce a pro-survival HSR will be identified.
The role of glial cells in HD

There is evidence that the onset and progression of HD
is both cell-autonomous and non-cell autonomous. One
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study showed that a transgenic mouse with panneuronal expression of Htt103Q developed pathologies
associated with end-stage disease, including astrogliosis,
motor deficits and neurodegeneration [82, 83]. However,
when Htt103Q expression was restricted to either striatal neurons or cortical pyramidal neurons, pathologies associated with end-stage disease did not develop
despite these cells having nuclear polyQ-expanded Htt
aggregates and alterations in NMDA receptor function [82, 83]. These studies showed for the first time
that HD pathogenesis and propagation depends on interactions between neuronal subtypes. Neuronastroglia interactions have also been implicated in the
non-cell autonomous progression of HD. A study that
investigated transgenic mice that expressed Htt98Q in
both neurons and astroglia observed that these mice
displayed more severe neurological symptoms and
earlier death compared to mice in which Htt98Q expression was restricted to either neurons or astroglia
alone [84]. Therefore, it seems likely that both
neuron-neuron and neuron-astroglia interactions are
responsible for the onset and progression of HD.
The combination of molecular pathologies that develop in neurons and astroglia work in tandem to
progress HD (Fig. 3). However, the mechanisms that
underlie astroglial-mediated toxicity in HD are only
partially understood. Astroglia expressing polyQexpanded Htt secrete neurotoxic factors and decrease
the expression of the glutamate transporters, GLAST
and GLT-1 [85–87]. Indeed, polyQ-expanded Httexpressing astroglia have been shown to increase the
vulnerability of striatal and cortical neurons in coculture to excitotoxic stresses [88]. Conversely, in coculture experiments, astrocytes expressing nonpathogenic Htt23Q protected 78% of the Htt130Q-expressing cortical neurons from glutamate toxicity [88].
Furthermore, conditioned medium derived from WT
astroglial cultures protects Htt111Q-expressing striatal
neuronal progenitor cells from neurotoxic insults (e.g.
H2O2, glutamate, 3-nitropropionic acid) [89].
With respect to neurotoxic factors secreted by
astroglia, an elegant study by Liddelow et al. [86],
demonstrated that pro-inflammatory microglia can activate a neurotoxic phenotype in astroglia (defined in
the work as A1 astroglia). They showed that A1
astrocyte formation is a pathological response of the
CNS in mice treated with systemic injections of lipopolysaccharide and acute CNS injury, and in patients
with NDs [86]. The proportion of neurotoxic (A1)
astroglia in the caudate nucleus of HD patients was
significantly greater than in controls (60% in HD tissue compared to 25% in the control) [86]. Furthermore, qPCR of A1 astroglia-associated transcripts
showed a 60-fold increase in the caudate nucleus of

San Gil et al. Molecular Neurodegeneration (2017) 12:65

HD patients compared to controls [86]. Thus, cell-cell
interactions and dysfunctions of striatal or cortical
pyramidal neurons and astroglia are likely to work
synergistically to progress HD into late-stages. Therefore, it is important to maintain astrocytes in the striatum in a healthy and neurotrophic condition to
minimize neurodegeneration in the striatum. The
focus of research investigating pro-survival mechanisms and the proteostasis network in HD has thus
far been predominantly focused on striatal neurons.
However, considering accumulating evidence that implicates astroglia in the pathogenesis of HD, it is relevant to also investigate these pathways in astroglia.

Page 8 of 20

expression decreases the levels of glutamate transporters
and induces a neurotoxic phenotype of astroglia. Indeed,
a recent study demonstrated that the over-expression of
the sHsp, αB-c, in astroglia ameliorates the pathologies
associated with HD in transgenic mice that express fulllength Htt97Q [92]. Over-expression of αB-c in astroglia
significantly reduced the number of large (> 1 μm)
Htt97Q inclusions in the striatum and cortex, and resulted in a 14% increase in the number of NeuN-positive
neurons in the striatum [92]. This provides an elegant
example of how increasing Hsps in astroglia can ameliorate HD neuropathologies in a non-cell autonomous
manner and provides support for increased investigation
into the HSR in astroglia in the context of HD.

The HSR in striatal astrocytes

Studies investigating HSR-inducing compounds have
provided valuable insights into the capacity of different
cell populations to induce an HSR in the absence of the
expression of polyQ-expanded Htt. Primary striatal astrocytes derived from WT mice showed a stronger induction of the HSR compared to striatal projection
neurons after treatment with the Hsp90 inhibitor, NVPHSP990: treated striatal astroglia showed an 18-fold increase in Hsp70 and 4-fold increase in Hsp25 mRNA
levels [90]. In contrast, NVP-HSP990 treated striatal
projection neurons only showed an 8-fold increase in
Hsp70, 3-fold increase in Hsp40, and no change in
Hsp25 mRNA levels [90]. In the vehicle treated mice,
there were no significant differences compared to nontreated mice in the synthesis of any of the Hsp mRNAs
investigated (Hsp70, Hsp40, Hsp90 or HSF1), with the
exception of Hsp25, which showed a 7-fold increase in
astroglia compared to striatal projection neurons [90].
Together these findings suggest that, in the absence of
polyQ-expanded Htt expression, striatal astroglia are
“pre-loaded” with greater levels of Hsp25 mRNA and
can induce a stronger HSR compared to striatal projection neurons.
The size and frequency of formation of polyQ-expanded
Htt inclusions varies across different cell-types in the CNS.
Striatal and frontal cortex glial fibrillary acidic protein
(GFAP)-positive astroglia demonstrated a significant reduction in the size and the proportion of cells with Htt210Q inclusions compared to neurons in these CNS regions in a
mouse model of HD [91]. This difference was attributed to
a possible increase in proteostasis network components (including heat shock proteins) in reactive astroglia. However,
there is insufficient evidence from models of HD, with
regards to the Hsp content of striatal astroglia, to draw relationships between inclusion size and number and proteostasis capacity of striatal astroglia (Fig. 3).
Determining mechanisms that maintain astroglia in a
healthy and neurotrophic state should be a priority in
future HD research, given that polyQ-expanded Htt

Summary of the HSR in HD

It has been demonstrated using a range of cell and animal models of HD that striatal neurons do not sense or
respond to polyQ-expanded Htt expression by upregulating Hsps. Moreover, striatal neurons expressing
polyQ-expanded Htt have an attenuated capacity to induce an HSR after heat shock. This could be due to decreased levels of HSF1 in striatal tissue observed in HD
models. In addition, the altered chromatin landscape
caused by histone H4 hypoacetylation at Hsp genes observed in a HD mouse model, may also lead to decreased binding of HSF1 to DNA, and down-regulation
of Hsp70 and Hsp40. In the absence of polyQ-expanded
Htt expression, striatal astroglia, compared to striatal
projection neurons, have greater levels of Hsp25 mRNA
and can induce a stronger HSR. However, the effect of
polyQ-expanded Htt on HSR induction in astroglia remains to be elucidated.
Previous research has demonstrated that a variety of
Hsps can inhibit polyQ-expanded Htt protein aggregation. However, the affected neurons in HD appear not to
sense the initial stages of pathogenic protein misfolding
as a cellular stress and therefore do not activate an HSR.
As the neurons and surrounding astroglia in the CNS
appear to be incapable of activating an HSR in the context of HD, therapeutics that can induce Hsp expression
in early stages of disease may prove beneficial.
Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis is characterized by a loss
of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. Only 5–10%
of ALS cases are familial (fALS) and some of these arise
from mutations in one of 13 (or more) genes leading to
the expression of aberrant aggregation-prone proteins.
Mutations in SOD1 (copper/zinc ion-binding superoxide
dismutase), FUS (fused in sarcoma), TDP-43 (TAR DNA
binding protein), CCNF (cyclin F) [93], OPTN (optineurin), ANG (angiogenin, ribonuclease, RNase A family,
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5), UBQLN2 (ubiquitin-like ubiquilin2), and others, as
well as repeat expansions in C9ORF72 (chromosome 9
open reading frame 72), are all associated with fALS (recently reviewed by [94, 95]). The remaining 90–95% of
ALS cases are idiopathic and sporadic. In ALS, motor
neurons are selectively susceptible to degeneration as a
consequence of mutant ALS-associated protein expression, despite the ubiquitous presence of these same mutant forms in neuronal and non-neuronal cells [96].
Motor neurons have functional and morphological characteristics that may make them particularly vulnerable to
toxic protein misfolding and aggregation, neuroinflammation, excitotoxic insults, oxidative damage and subsequent degeneration in ALS [96]. For example, motor
neurons have a high metabolic load, high energy demands, long axons, and rely on rapid signaling of neurotransmitters to other neurons and muscle tissue by
axonal transport. Malfunction of each of these characteristics of motor neurons have been associated with ALS
pathology (for reviews see [97–99]). In addition, recent
findings have shown that multiple housekeeping and
stress-response pathways involved in maintaining proteostasis (e.g. the ubiquitin proteasome system and
endoplasmic reticulum unfolded protein response) are
dysregulated in ALS-affected motor neurons, which
would further exacerbate their degeneration [96, 100–
105]. However, it remains to be established whether affected cell-types in the CNS can induce an HSR as a result of pathogenic protein aggregation associated with
ALS as a protective response to this chronic proteotoxic
stress.
The HSR in motor neurons

Motor neurons may have a relatively high threshold for
HSR induction compared to surrounding non-neuronal
cells. Batulan et al. [53] investigated the endogenous expression of HSF1 in motor neurons and their capacity to
activate the HSR. In these studies, immunohistochemistry of motor neurons in spinal cord cultures demonstrated the presence of HSF1, but not Hsp70, in these
cells. The capacity of motor neurons to induce an HSR
was assessed following heat shock (42 °C for 1 h) by
monitoring the stress-inducible expression of an Hsp70
promoter driven EGFP construct. The lack of EGFP
fluorescence in motor neurons after heat shock suggested that HSF1 was not activated and thus did not
bind to the HSE used in this reporter construct [53].
Other studies have also shown that spinal cord motor
neurons in situ fail to transcribe and express Hsp70 following heat shock [58, 106]. However, it is not clear
from this work whether HSF1 was (i) not activated and
therefore not capable of binding DNA and/or (ii) not
present at sufficient levels in these cells to induce an
HSR.
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To determine which of these possibilities was responsible
for these observations, WT HSF1 (HSF1WT) and a constitutively active mutant of HSF1 (HSF1+) were overexpressed in primary murine motor neurons [53]. Simply
increasing the level of HSF1WT in cells was not sufficient to
enhance their capacity to express Hsp70 [53]. Conversely,
over-expression of HSF1+ resulted in an up-regulation of
Hsp70, Hsp40, and Hsp25 levels in 96.1 ± 3.4%, 100 ± 0%,
and 14.6 ± 7.3% in motor neurons, respectively [53, 107].
Furthermore, expression of HSF1+ in motor neurons expressing pathogenic SOD1G93A significantly reduced the
formation of inclusions and conferred cytoprotection, compared to HSF1WT [107]. Together, these findings suggest
that the attenuated capacity of motor neurons to induce an
HSR in the context of heat shock is due to their inability to
activate HSF1, not insufficient levels of HSF1 in these cells
(Fig. 4).
The over expression and aggregation of mutant SOD1
(mSOD1) in mouse models may not be sufficient to induce an HSR in motor neurons. Primary murine motor
neurons expressing mSOD1 demonstrate no change in
expression levels of Hsp70, Hsp105, Hsp90, Hsp60, or
Hsp40 compared to those expressing SOD1WT and nontransgenic control motor neurons (Table 2). Furthermore, a reduction in Hsp105 levels was observed in
spinal cord tissue homogenates of SOD1G93A mice [108].
Hsp105 is a chaperone expressed in neurons and glia- in
the CNS and can inhibit the aggregation of mSOD1 in
cell-based models [108]. Therefore, the decline in
Hsp105 expression, combined with the inability of rodent motor neurons to up-regulate Hsp70, Hsp90,
Hsp60, or Hsp40, suggests that the HSR is either unable
to be activated or is impaired in these models of ALS
(Fig. 4).
In the absence of disease, the endogenous and constitutive expression of Hsp27 in motor neurons of the
spinal cord plays an important role in the housekeeping
of proteostasis. Hsp27 is a well characterized molecular
chaperone that also has potent anti-apoptotic functions
[109]. Hsp27 can inhibit the release of mitochondrial
cytochrome c and associate with Daxx, thereby inhibiting a motor neuron-specific apoptosis pathway mediated
by Fas-Ask1-p38 [109–112]. However, in transgenic
mouse models Hsp25 levels become dysregulated and
decline in motor neurons during ALS progression (Table
2). Studies have shown that pre-symptomatic mSOD1
mice have Hsp25 levels comparable to age-matched controls [113, 114]. However, immediately prior to the onset
of disease symptoms, Hsp25 levels decline in spinal cord
motor neurons as demonstrated by immunohistochemistry of spinal cord sections [113, 114]. In contrast, by the
late stages of the disease, both Hsp25 and αB-c are upregulated in spinal cord astroglia, a finding consistent in
numerous studies [79, 113–116]. Future research could
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Fig. 4 Proposed mechanism of the HSR and its components in motor neurons and astroglia of mSOD1 over-expressing models of ALS. Motor neuron
disease initiation and progression is dependent on the molecular pathologies developed in motor neurons (e.g. formation of mSOD1 aggregates or JUNQ)
and astroglia (e.g. secretion of unidentified toxic “factors”). The susceptibility of motor neurons to degeneration is likely due to an inability of motor neurons
and astroglia to induce a cytoprotective HSR in response to increasing quantities of misfolded proteins (e.g. mSOD1). (1 and 2) HSF1 in motor neurons has a
relatively high threshold for activation and the over-expression of mSOD1 and subsequent molecular pathologies do not activate HSF1
nor induce HSF1 binding to DNA. (3) There is no detectable basal expression or up-regulation of Hsps in mSOD1 over-expressing motor
neurons, with the exception of (4) Hsp27, which gradually declines with disease progression. (5) Astroglia in mSOD1 over-expressing mice
have increased amounts of Hsp27 and αB-c with disease progression; however, the levels of other Hsps are not changed. (6) There have
been few investigations regarding HSF1 activation and DNA-binding in astroglia in the context of ALS. Therefore, the capacity of mSOD1
over-expressing astroglia to activate HSF1 and induce an HSR remains unknown. (7) There is increasing evidence that extracellular vesicles
containing Hsps are secreted by astroglia, and these vesicles are endocytosed by motor neurons and facilitate transfer of Hsps

address whether this decline in Hsp25 in mSOD1 expressing motor neurons correlates with an increase in
Hsp25 sequestered in insoluble protein deposits. This
could be achieved by immunoblot analysis of soluble
and insoluble protein fractions and immunohistochemistry. The decrease in Hsp25 in motor neurons during the
later stages of ALS in these transgenic mouse models
may increase their susceptibility to neurodegeneration as
a consequence of toxic protein accumulation and other
ALS-related stresses (Fig. 4).
With regards to ALS in humans, immunohistochemistry of human motor neurons in cervical spinal cord sections obtained at autopsy showed no change in Hsp70 or
Hsp27 levels compared to age-matched controls [53].
The combined evidence suggests that the toxicity of
mSOD1 in spinal cord motor neurons is not sufficient to
elicit the stress-inducible expression of Hsps in rodents

or humans. In contrast, Hsp70 (but not Hsp27) immunoreactivity was occasionally observed to be higher in
neighboring glial cells in fALS or sporadic ALS patients
[53]. This suggests that astroglia in humans and rodents
are capable of up-regulating certain Hsps in response to
stresses associated with ALS. This further supports the
hypothesis that motor neurons intrinsically have a high
threshold for induction of the HSR and suggests that
misfolded mSOD1 can go undetected by this inducible
arm of the proteostasis network in these cells.
There is a lack of diversity in the models that have been
used in work investigating the HSR in association with
ALS. Data regarding neuronal and glial Hsp expression in
ALS is derived primarily from mSOD1 rodent models,
with the exception of one study that used the TDP43WT×Q331K transgenic mouse model of ALS [117]. Therefore, it remains to be determined whether these findings
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Table 2 List of Hsps and whether their expression is up-regulated (↑), down-regulated (↓), or not changed (No Δ) in rodent models
of motor neuron disease at the late-stage of disease compared to age-matched transgenic WT or non-transgenic mouse controls
Hsps
HSF1
αB-c (HSPB5)

Transgenic disease models

Tissue or cell type

Reference

TDP-43

IB: ↓ spinal cord tissue homogenates

[117]

SOD1G93A

IB: ↓ spinal cord tissue homogenates

[174]

IHC: ↑ spinal cord astroglia
IHC: ↓ spinal cord oligodendrocytes

[115]

SOD1G93A

IHC: ↑ spinal cord astroglia

[116, 175]

G37R

WT×Q331K

SOD1

L126Z

SOD1

IHC: ↑ spinal cord astroglia

[116]

Hsp22 (HSPB8)

SOD1G93A

IHC: ↑ spinal cord motor neurons

[176, 177]

Hsp25 (HSPB1)

G93A

SOD1

IHC: ↑ spinal cord astroglia
IHC: ↓ spinal cord oligodendrocytes

[53, 113, 114, 116]

SOD1G37R

IHC: ↑ astroglia in the inferior colliculus, cerebellar
white matter, brain stem, spinal cord

[79]

IHC: ↓ spinal cord motor neurons

[115]

IHC: ↑ spinal cord astroglia
IHC: ↑ spinal cord undefined neurons

[178]

SOD1L126Z
SOD1G93A
,
Hsp40

Hsp60

SOD1

G37R

, SOD1

H46R/H48Q

, SOD1

SOD1G93A

IHC: No Δ spinal cord

[79]

SOD1G93A
SOD1G85R, SOD1G37R, SOD1H46R/H48Q
,

IB: No Δ spinal cord tissue homogenates

[178]

TDP-43WT×Q331K

IB: No Δ spinal cord tissue homogenates

[117]

SOD1G93A

IHC: No Δ spinal cord

[79]

H46R/H48Q

IB: No Δ spinal cord tissue homogenates

[178]

SOD1G93A
SOD1G85R, SOD1G37R, SOD1H46R/H48Q
,

IB: No Δ spinal cord tissue homogenates

[53, 79, 115, 178]

SOD1G93A
,
Hsp70

G85R

G85R

SOD1

G37R

, SOD1

, SOD1

SOD1

IHC: ↑ “sick-appearing” spinal cord motor neurons

[179]

SOD1G85R

IB: ↑ spinal cord tissue homogenates

[145]

SOD1G93A

IHC: No Δ spinal cord

[79]

SOD1G93A
SOD1G85R, SOD1G37R, SOD1H46R/H48Q
,

IB: No Δ spinal cord tissue homogenates

[178]

SOD1G93A

IB: ↓ in spinal cord tissue homogenates

[108]

G93A

Hsp90

Hsp105

These results are from immunoblot (IB) or immunohistochemical (IHC) staining and microscopy of different CNS regions

also apply to other fALS-associated mutations (e.g. FUS).
This is of particular relevance if each aggregation-prone
protein engages a specific set of Hsps, as has been previously proposed [118]. Therefore, additional research is required in other rodent models of ALS to advance our
understanding of the HSR in this disease.
The role of glial cells in ALS

There is strong evidence that ALS can be characterized as
a non-cell autonomous disease [99, 119]. As such, ALS
initiation and progression depends on both the molecular
pathologies developed within motor neurons, and the
subsequent reactivity of surrounding non-neuronal cell
populations such as astroglia and microglia. For example,
transgenic mice expressing SOD1G37R specifically in
motor neurons in the ventral horn of spinal cords
remained healthy for up to 1.5 years of age compared to
mice that ubiquitously express this mSOD1 isoform,
which die at 4 months of age [120, 121]. Moreover, knock
out of SOD1G37R expression in motor and dorsal root
ganglion neuron progenitors of transgenic mice results in

an 18 day delay to disease onset and 31 day delay to early
disease progression compared to controls [122]. Together,
these findings demonstrate that mSOD1 expression in
motor neurons plays a role in early disease initiation and
mSOD1 expression in other cells is required for disease
progression. In support of this, selective deletion of
SOD1G37R expression from GFAP-positive spinal cord
astroglia or cluster of differentiation molecule 11B
(CD11b)-positive microglia did not slow disease onset or
early disease progression, but significantly delayed late
disease progression resulting in an overall extension of
survival by 60 and 99 days, respectively [122, 123]. These
two studies demonstrate that mSOD1 expression in astroglia and microglia plays a significant role in late disease
progression and overall survival. This work and the work
of many others emphasizes the importance of astroglia
and microglia in the pathogenic cascade associated with
ALS (for in-depth reviews examining the non-cellautonomous nature of ALS see [99, 119, 124]).
The non-cell-autonomous progression of ALS by glial
cells has also recently been demonstrated in a mutant
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TDP-43 model of ALS [125]. In a TDP-43Q331K expressing transgenic mouse model of ALS, cre recombinase
excision of the TDP-43Q331K transgene from motor neurons completely rescued motor neuron death [125].
However, despite the increase in motor neuron survival,
there was no significant difference in the number of degenerating axons and neuromuscular junctions or glialmediated neuroinflammation in end-stage disease mice
when the TDP-43Q331K transgene was excised in motor
neurons [125]. These findings are supported by research that showed that astroglial-specific expression
of TDP-43M337V in rats results in the death of spinal
cord motor neurons and denervation of skeletal muscles [126]. One proposed mechanism for the neurotoxicity of astroglia in mutant TDP-43 expressing
models is that neurotrophic genes are suppressed and
neurotoxic genes are up-regulated (e.g. LCN2 and
CHI3L1) [127]. Combined, these studies suggest that
the expression of mutant TDP-43 in astroglia is sufficient to cause non-cell-autonomous death of motor
neurons. Furthermore, the non-cell-autonomous progression of ALS is not confined to mSOD1-expressing
mouse models, but may represent a generic mode of
ALS progression.
The ubiquitous expression of mutant ALS-associated
protein in the CNS may not alone facilitate the transition of astroglia from a neurotrophic to neurotoxic
phenotype in ALS. Co-culture with A1 astrocytes induces the rapid death of a range of neurons, including
spinal cord α-motor neurons [86]. Interestingly, there
was a significant increase in the proportion of A1 astroglia in the motor cortex of patients with ALS (40% of
ALS astroglia were A1 compared to 15% in controls)
[86]. Likewise, there was a 60-fold increase in A1-related
transcripts in the motor cortex of ALS patients compared to controls [86]. The mechanism by which these
A1 astrocytes induce toxicity was proposed to be
through the secretion of a ‘toxic factor’ [86]. Other studies have also suggested that mSOD1-expressing astrocytes release a soluble ‘toxic factor’, which significantly
reduces the viability of motor neurons in co-culture
[128–131]. The identity of this neurotoxic factor is currently unknown and additional research is required to
determine its mode of action. In any case, it is important
to consider cytoprotective mechanisms that maintain the
neurotrophic functions of glia in ALS, such as the HSR
leading to Hsp expression.
The HSR in astroglia

It is generally regarded that astroglia are capable of activating an HSR in response to stress, including whole
animal hyperthermia [51, 57–59]. In the context of ALS,
astroglia have higher levels of the sHsps, αB-c and
Hsp25, compared to WT controls at the end-stage of
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disease, but not Hsp90, Hsp70, Hsp60 or Hsp40 (Table
2, Fig. 4). Interestingly, these findings suggest that the
over-expression of unstable and misfolded mSOD1
species in the CNS fails to activate the HSR. Moreover,
the expression of sHsps and other Hsp families may not
be under the same transcriptional and translational
controls.
In astroglia, there is a scarcity of published work
investigating HSF1-activation and HSR induction at the
molecular level using biochemical techniques (Fig. 4).
However, the discord between sHsps being up-regulated
and other Hsps not being affected in astroglia in the
context of ALS suggests that there are additional layers
of regulation of the HSR in these cells that are either
HSF1-mediated or post-translational. In recent work,
Zheng et al. [28] hypothesized that the phosphorylation
of HSF1 at serine and threonine residues serves to finetune HSF1 transcription at promoter regions, rather
than acting solely as an on/off switch. Thus, HSF1 phosphorylation could serve to regulate the kinetics and
magnitude of the HSR in a cell-type dependent manner.
Additional unidentified mechanisms of HSF1 regulation,
including those that are cell-type specific, could explain
the complete absence of HSR induction in motor neurons compared to astroglia in mSOD1-expressing transgenic mice. In fact, the HSF1-mediated HSR in the
different cell-types that comprise the CNS is likely to be
much more complex than our current models of HSR
induction and attenuation (Fig. 2), which are based primarily on findings from Saccharomyces cerevisiae, Drosophila melanogaster, cell-lines or studies using
recombinant human HSF1 in solution [38, 132–134].
Future research should elucidate mechanisms of HSR induction in astroglia, particularly astroglia that are affected in the spinal cord in ALS.
Knowledge of the precise mechanism by which HSF1
mediates the induction of specific Hsps in astroglia is
important as it may uncover new therapeutic targets for
the rescue of motor neurons from degeneration associated with ALS progression. This knowledge could be
harnessed to up-regulate specific sets of Hsps that have
been shown to interact with aggregating proteins associated with ALS [118]. For example, Hsp70 and HspB8
interact with TDP-43 and Hsc70, Hsp70, DNAJB1,
DNAJB2a/b, Hsp27, αB-c, and HspB8 interact with
SOD1 to prevent protein aggregation and decrease cytotoxicity [118]. It has been proposed that other Hsps are
also likely to prevent the aggregation of TDP-43 and
SOD1 since there are numerous ‘non-canonical’ members of the Hsp families that have not been tested for
anti-aggregation or anti-apoptotic activities in these
assays [118]. Up-regulation of cytoprotective Hsps in
astroglia could maintain them in a healthy neurotrophic
state to support motor neuronal viability and prevent
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conversion of astroglia to a neurotoxic (A1) phenotype.
However, further research is needed to investigate mechanisms of HSF1-mediated HSR induction across different CNS cell-types in the presence and absence of
disease-associated protein aggregation.
One mechanism by which astroglia may provide
cytoprotection to motor neurons is through the exchange of extracellular vesicles containing Hsps [135].
Extracellular vesicles derived from chick spinal cord
primary astroglial cultures following heat shock contain Hsp70 and Hsc70 [136]. In another study investigating glial-neuronal interactions, T98G glioma cells
were shown to secrete Hsp70 into the culture
medium and LA-N-5 neuroblastoma cells took up
this Hsp70 [137]. The Hsp70 uptake increased the
stress tolerance of the LA-N-5 cells to heat shock
and staurosporine-induced apoptosis [137]. It would
be interesting to extend on this work to investigate
whether extracellular vesicles from more physiologically relevant cell-models (e.g. primary murine astroglia
and motor neurons) also facilitate the trafficking of
Hsps. The mechanisms of astroglial exocytosis and
neuronal endocytosis used to traffic Hsps are also yet
to be elucidated. This non-cell-autonomous mechanism(s) by which astroglia provide products of the
HSR to neurons could be exploited to increase Hsp
levels in motor neurons. This strategy could enhance
the stress tolerance of motor neurons and decrease
degeneration in the spinal cord in ALS (Fig. 4).

Summary of the HSR in ALS

Spinal cord motor neurons from primary cell or animal
models of ALS are unable to activate HSF1 and hence
lack a stress-induced up-regulation of Hsps. The levels
of Hsp27 in motor neurons decline with disease progression. Motor neurons have an inherently high threshold
for the activation of the HSR and the expression and accumulation of mSOD1 in the cell is not sufficient to activate the HSR. In contrast, spinal cord astroglia have
elevated levels of αB-c and Hsp25 (rodent) or Hsp70
(human) at the end-stage of disease. However, the precise mechanisms by which these Hsps are up-regulated
are unknown. Overall, there is a distinct lack of research
into the HSR in spinal cord astroglia and its potential
role in ALS.
Due to the non-cell-autonomous nature of ALS, future
research should focus on maintaining affected spinal
cord astroglia in a neurotrophic state to support motor
neuron viability. Furthermore, investigation of Hsp70
(and other Hsp) transfer between astroglia and motor
neurons could represent an exciting new mechanism for
the development of therapeutics that target the proteostasis network in ALS.
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Studying the therapeutic effects of increasing HSR
components
The plaques and inclusions that are characteristic of
ALS, HD and other NDs all share common morphological and biochemical features and this points to the
highly related nature of these diseases [138, 139]. In
addition, plaques and inclusion bodies are co-localized
with various components of the proteostasis network,
which may represent an irreversible sequestration and
subsequent loss of function of these vital housekeeping
components [140]. The sequestration of these chaperones, in conjunction with the possibility that toxic misfolded proteins are not sufficient to induce an HSR in
the CNS, are likely to be important molecular mechanisms that lead to neurodegeneration in these diseases.
However, there appears to be mechanistic differences in
the way that these pathological proteins inhibit or evade
detection by the HSR. In the case of Htt, there is evidence to suggest that the misfolded proteins themselves
may directly impair mechanisms of the proteostasis network by changing the chromatin landscape (Fig. 3). The
absence of a stress-induced up-regulation of Hsps in
early disease allows the formation of toxic protein species, which precede a cascade of cellular dysfunctions in
NDs. Therefore, in the absence of an HSR in affected
neurons and surrounding glia in the CNS, boosting the
HSR pharmacologically represents a promising therapeutic intervention for the treatment of these diseases at
an early stage.
A significant amount of work has investigated the effects of over-expressing individual Hsps or activating an
HSF1-mediated HSR in rodent models of NDs (for comprehensive reviews see [9, 36, 140–144]). Determining
which of the HSR components are the most efficacious
in preventing protein aggregation and subsequent neurotoxicity is an important step in elucidating targets for
the development of therapeutics that ameliorate NDs.
Over-expression of individual chaperones in mSOD1
mouse models of ALS has resulted in modest effects
with regards to a reduction in the amount of insoluble
protein and increased motor neuron survival (Table 3)
[145–150]. However, this does not correlate with an increase in overall survival of the double transgenic animals (Table 3) [145–150]. Conversely, up-regulation of
the HSR by treatment with withaferin A, celastrol or arimoclomol results in an increase in the number of surviving motor neurons and the lifespan of mSOD1
expressing mice [151–154]. This same trend was observed in mouse models of HD, whereby overexpression of HSJ1a and Hsp70 has no effect on overall
survival but over-expression of an active mutant of
HSF1 extended survival by 15 days (Table 4) [155]. The
exceptions to this are DNAJB1, DNAJB6 and QBPHsc70 binding motif which, when over-expressed, were
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Table 3 The effect of the over-expression of Hsps and up-regulation of the HSR on the molecular pathologies developed in rodent
models of MND
Transgenic model/
MND
Therapeutic compound model
Hsp27 Tg

Increase in Hsp in Tg mouse Extended
lifespan

% ↑/↓ in surviving % ↑/↓ in levels References
motor neurons
of inclusions

SOD1G93A

40-fold ↑spinal cord
No Δ (prolonged 4.2 days) –
25-fold ↑ cortex, cerebellum,
hippocampus
Expressed in MN + GFAP+ve
astroglia

No Δ

[146]

SOD1G93A

–

No Δ (died 6 days sooner) 24% ↑

No Δ

[147]

HSJ1a Tg

SOD1

7-fold ↑

No Δ

No Δ

[148]

Hsp70 Tg

SOD1G93A

10-fold ↑

No Δ (prolonged 1.4 days) –

–

[145]

G93A

SOD1

10-fold ↑ spinal cord

No Δ

–

–

SOD1G37R

10-fold ↑

No Δ

–

–

rhHsp70 injected 3× weekly
(20μg)- detected in muscle
not CNS

9 days

12.5% ↑

–

[149]

G85R

G93A

Hsp70 administered
exogenously

SOD1

HSF1 Tg

SOD1H46R/H48Q 3-fold ↑

SIRT1 Tg

SOD1G93A

Withaferin A

Celastrol

61% ↑

No Δ

–

34% ↓

[151]

3-fold ↑

15 days

–

40% ↓

[150]

SOD1

2.6-fold ↑ Hsp25
2.2-fold ↑ Hsp70
Phosphorylated HSF1

8 days

30% ↑

39% ↓

[152]

SOD1G37R

–

18 days

–

–

SOD1G93A

–

16 days

30% ↑

–

[153]

G93A

Arimoclomol

SOD1

3-fold ↑ Hsp70
2.5-fold ↑ Hsp90
Phosphorylated HSF1

28 days

74% ↑

–

[154]

NXD30001

SOD1G93A

No ↑ in Hsps in the CNS
↑ Hsp70 in skeletal muscle

–

–

–

[170]

G93A

Double transgenic (Tg) mice were bred for the over-expression of an Hsp and a SOD1 mutant associated with ALS. Alternatively, mice that over-express mSOD1
were treated with a therapeutic compound for the activation of the HSR. The fold increase in Hsp levels (and, if reported, the tissue-type in which this occurs),
number of extended days of life, percent increase (↑) or decrease (↓) in spinal cord motor neurons, and percent ↑ or ↓ in the levels of inclusions is reported for
each study

capable of reducing insoluble Htt and extending survival
by 17, 21 and 32 days, respectively [156–159]. These
findings illustrate how specific sets of Hsps may be more
efficacious against aggregating proteins associated with
HD. Furthermore, molecules that activate HSF1 and upregulate the HSR (and therefore increase expression of a
broad range of stress-related proteins) appear to be
more capable of reducing protein aggregate load, preventing neurodegeneration and increasing lifespan of
mouse models of NDs compared to up-regulation of individual chaperones.
Investigations into the therapeutic benefit of pharmacological activation of the HSR in the context of NDs are
currently in progress. There are two classes of therapeutics under investigation, each target different aspects of
the HSR pathway. One class of therapeutics activate HSF1
and/or up-regulate downstream products of the HSR.
These include celastrol, arimoclomol, withaferin A, acetyl,
L-carnitine and pyrrolidine dithiocarbamate [160–164].
Thus far, arimoclomol is the most promising HSRmediating therapeutic. Administration of arimoclomol to

mouse models of ALS (10 mg/kg/day), spinal and bulbar
muscular atrophy (120 mg/kg/day) and inclusion body
myositis (120 mg/kg/day) ameliorated neuropathologies
associated with each disease, and arimoclomol successfully
passed phase I human clinical trials in 2008 [154, 165–
167]. However, there is currently limited information
regarding that status of phase II/III trials of arimoclomol
in ALS patients.
Another class of therapeutics targets the HSF1 inhibitory complex composed of Hsp90, co-chaperone p23 and
immunophilin FK506-binding protein 5. Since, Hsp90
activities are ATP-dependent, this complex can be
targeted by small molecules that compete with ATP for
binding to Hsp90. Radicicol, NVP-HSP990, geldanamycin
and geldanamycin-derived 17-allylaminogeldanamycin are
Hsp90 inhibitors that act in this way and have been investigated for the treatment of NDs [72, 75, 168, 169]. In HD
mouse models, NVP-HSP990-induced induction of the
HSR in CNS tissues but this effect declined with increasing age of mice and despite a 20% decline in inclusion
load, no extension of life was observed [75]. Furthermore,
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Table 4 The effect of the over-expression of Hsps and up-regulation of the HSR on the molecular pathologies developed in rodent
models of HD
Transgenic model/Therapeutic
compound

HD
model

Increase in Hsp in Tg mouse Extended
lifespan

% ↑/↓ in
% ↑/↓ in levels of References
surviving neurons inclusions

αB-c Tg (astroglia only)

BACHD

–

–

12.5% ↑

50% ↓

[92]

Hsp27 Tg

R6/2

12-fold ↑

–

–

No Δ

[180]

Hsp70 Tg

R6/2

Rat Hsp70

–

–

No Δ

[72]

5–15-fold ↑ human Hsp70

No Δ

No Δ

No Δ

[181]

Injected into the striatum

32 days

–

90.8% ↓

[158]

rAAV-QBP1-Hsc70
binding motif

R6/2

rAAV-DNAJB1

R6/2

Injected into the striatum

17 days

–

39.2% ↓

[159]

DNAJB6 Tg

R6/2

Brain-specific up-regulation
(nestin promoter)

21 days

–

33% ↓

[157]

HSJa Tg

R6/2

Brain specific up-regulation

No Δ

No Δ

35% ↓

[182]

Hsp104

N171-82Q
HD

“Strongly” expressed in the
brain, heart kidneys, testis

–

–

No Δ

[183]

HSF1Active Tg

R6/2

Expressed in skeletal muscle, 15 days
heart and testes

No Δ

79% ↓

[155]

NVP-HSP990
treatment

R6/2

2.7-fold ↑ Hsp70
3.8-fold ↑ Hsp25
1.6-fold ↑ Hsp40

No Δ

–

20% ↓

[75]

HSF1 KO

R6/2

–

105 day decrease –
in lifespan

15% ↑

[184]

HSF2 KO

R6/2

–

91 day decrease
in lifespan

–

20% ↑

[185]

Double transgenic (Tg) mice were bred for the over-expression of an Hsp and polyQ-expanded Htt associated with HD. Alternatively, HSF1 and HSF2 genes were
knocked-out (KO) of HD mouse models. Lentiviral vectors for the expression of QBP1-Hsc70 binding motif and DNAJB1 were injected directly into the striatum of
R6/2 mice. In one case, mice that over-express polyQ-expanded Htt were treated with NVP-HSP990, a therapeutic compound for the activation of the HSR. The fold
increase in Hsp levels (and, if reported, the tissue-type in which this occurs), number of extended days of life, percent increase (↑) or decrease (↓) in spinal cord
motor neurons, and percent ↑ or ↓ in the levels of inclusions is reported for each study

in ALS mouse models, NXD30001 failed to induce the
HSR in the CNS, despite the brain permeability of this
molecule [170]. In vivo assessments investigating the efficacy of these compounds in the induction of the HSR has
led to the conclusion that Hsp90 inhibitors are cytotoxic
and not promising candidates to pursue for clinical trials.
A novel molecule identified in a yeast-based highthroughput screen, HSF1A, activates HSF1 by interacting with components of the inhibitory TRiC/CCT complex [171]. Treatment of cells with HSF1A results in
HSF1 nuclear accumulation, trimerization, and enhanced binding to DNA [171]. Treatment of PC12 cells
expressing polyQ-expanded Htt with HSF1A resulted
in the reduction of inclusion bodies formed and protected cells against toxicity [171]. Furthermore, recent
evidence shows that treatment of Neuro-2a cells transfected to express TDP-43-ΔNLS-K145Q with HSF1A
results in a ~ 60% reduction in the number of aggregates formed compared to the vehicle control [172].
This indicates that the activation of endogenous HSF1
by HSF1A is sufficient to suppress mutant TDP-43 expression in this cell-based model [172]; however, it remains to be established whether HSF1A provides
protection in vivo, in transgenic mouse models of NDs.

The therapeutic strategy of activating HSF1 in the
CNS in the context of NDs is a promising one. Over 3
decades of research has provided strong in vitro evidence that activating HSF1 can reduce protein inclusion
formation and ameliorate other molecular pathologies
associated with a range of NDs [155, 172, 173]. However,
progress towards the development of therapeutic compounds, that activate the HSR in affected tissues and
cell-types in NDs has been slow. This is the likely due to
the complexity of HSR induction in vivo, for example, in
CNS tissues, Hsps may be provided to neurons in a noncell autonomous manner that cannot be assessed in initial drug screens that are performed in vitro. Drug
screens need to move beyond simple cell-based models
and begin to incorporate more advanced tissue culture
approaches to consider the responses from the multiple
cell types present in tissues.

Conclusions
This review has highlighted the complexity of the HSF1mediated HSR and demonstrated that the generic model
for its induction and attenuation does not take into account additional layers of regulation that are stress- and
cell-type specific. This review highlights that regulation
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in the induction of the HSR differs not only between cell
types (e.g. neurons and astroglia) but also between neuronal sub-types in different regions of the brain (e.g. striatal neurons and motor neurons). It is these regulatory
aspects of the HSR that are of particular interest with
regards to the cells that comprise the CNS, where protein inclusion formation associated with NDs occurs.
We propose that the appearance of protein inclusions in
discrete neuronal populations in NDs may result from
low (or no) basal levels of Hsps and/or a high threshold
of HSR induction in these cells. Indeed, two recent findings in an α-synucleinopathy and HD suggest a possible
generic underlying pathology in NDs, whereby HSF1 is
targeted for degradation by the proteasome through elevated expression or activity of ubiquitinases [25, 74].
Furthermore, evidence from a range of models of
NDs indicates that the species formed during protein
misfolding and aggregation do not cause sufficient cellular stress to induce an HSR in affected neurons and
astroglia. This suggests that cell-autonomous and noncell-autonomous mechanisms that maintain protein
homeostasis are insufficient to prevent protein aggregation associated with NDs in the CNS and highlights that
the HSR is a promising pathway to target in the development of novel therapeutics for these diseases.
Future research should investigate basal and stressinducible HSR proteins in neurons and astroglia, preferably using quantitative, high throughput and single-cell
analysis techniques, which circumvent contamination by
other cell types. This is particularly important due to the
growing body of evidence that implicates neuronalastroglial interactions in the progression of ALS and HD
into late- and end-stage disease (as is also the case for
other NDs). In addition, it is important to investigate the
mechanisms by which astroglia can be maintained in a
neurotrophic (rather than neurotoxic) phenotype in
NDs. In compiling this review, it highlighted to us that
there is a scarcity of research that has investigated the
HSR in astroglia in the context of ALS or HD (and indeed most NDs). Furthermore, the ability of astroglia to
provide non-cell-autonomous support to neurons by
trafficking Hsps and other neurotrophic factors in exosomes is currently understudied in physiologically relevant models. Future research in this field should
investigate the HSR in NDs by adopting a more holistic
approach and focus on defining the cell-autonomous
and non-cell-autonomous HSR within different cellstypes of the CNS.
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